In a randomized, placebo-controlled phase-2 trial performed by Eich et al., an anti-IL-17A monoclonal antibody given over a period of 12 weeks did not show significant effects in patients with moderate-to-severe symptomatic COPD. The gene discussed is IL17A; the disease is chronic obstructive pulmonary disease.